- Home
- ACGLO vs EXEL Comparison
ACGLO vs EXEL Comparison
Compare ACGLO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
ACGLO
Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F
Current Price
Company Overview
Basic Information| Metric | ACGLO | EXEL |
|---|---|---|
| Founded | N/A | 1994 |
| Country | Bermuda | United States |
| Employees | 5800 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | ACGLO | EXEL |
|---|---|---|
| Price | $20.27 | $46.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 24 |
| Target Price | N/A | ★ $45.18 |
| AVG Volume (30 Days) | N/A | ★ 2.6M |
| Earning Date | N/A | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | N/A | ★ 2.38 |
| Revenue | N/A | ★ $2,288,218,000.00 |
| Revenue This Year | N/A | $9.84 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | ★ N/A | $19.57 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | N/A | $31.90 |
| 52 Week High | N/A | $49.62 |
Technical Indicators
Market Signals| Indicator | ACGLO | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 23.61 | 69.33 |
| Support Level | $20.13 | $40.83 |
| Resistance Level | $20.75 | $47.24 |
| Average True Range (ATR) | 0.22 | 1.24 |
| MACD | -0.07 | 0.42 |
| Stochastic Oscillator | 3.81 | 88.91 |
Price Performance
Historical ComparisonAbout ACGLO Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.